NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

C4 Therapeutics, Inc. (CCCC) Stock Analysis

C4 Therapeutics, Inc. (CCCC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CCCC

$3.76

+$0.02 (+0.53%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CCCC with… →

CCCC Key Statistics

As of Sep 4, 2026
Trading
Open
$3.72
Previous Close
$3.74
Day's Range
3.66–3.85
52-Week Range
1.69–5.17
Volume
2.36M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.94
Valuation
Market Cap
$462.57M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.20
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.92
Financials (FY)
Revenue (FY)
$35.95M+1.02%
Net Income (FY)
−$104.99M
Profit marginThe share of revenue left as profit after all costs and taxes.
−289.44%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
123.03M
1-Year Return
+40.82%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
3.00M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CCCC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+96.86%
2025−46.94%
2024−36.28%
2023−4.24%
2022−81.68%
2021−2.81%
2020 (partial year)+29.97%

As of September 4, 2026.

CCCC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$35.95M−$104.99M−292.1%
2024$35.58M−$105.32M−296.0%
2023$20.76M−$132.49M−638.3%
2022$31.10M−$128.18M−412.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$35.95M—−$104.49M−$104.99M−292.1%
2024$35.58M—−$117.18M−$105.32M−296.0%
2023$20.76M—−$139.03M−$132.49M−638.3%
2022$31.10M—−$129.53M−$128.18M−412.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CCCC Valuation vs Biotechnology Median

Median of 656 stocks
MetricCCCCBiotechnology medianvs median
P/S ratio13.2015.2614% below
Profit margin−289.44%0.00%289.4 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values C4 Therapeutics, Inc. (CCCC) at $462.57M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 104.

Over the past 52 weeks the price has ranged from $1.69 to $5.17. The most recent close on file for CCCC is $3.76, dated September 4, 2026. That is +$0.02 (+0.53%) against the previous close. The latest close sits 122.49% above that 52-week low.

Financial Health

In fiscal 2025, C4 Therapeutics, Inc. reported revenue of $35.95M. That is +1.02% against the prior fiscal year, when revenue was $35.58M. The same year closed with a net loss of $104.99M. The reported profit margin is −289.44%. That is 289.4 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.92.

Across the 4 fiscal years on file, revenue moves from $31.10M in 2022 to $35.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 13.2 times revenue. On price-to-sales that is 13.51% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +40.82%. Across 5 years the annualized return works out at −38.89%. Beta against the wider market is reported at 2.95. Annualized volatility over the trailing 5 years is 117.66%.

Growth & Income

No dividend is on file for CCCC.

So far in 2026 the price is +96.86%. Across the complete calendar years on file, 2021 returned −2.81% and 2022 returned −81.68%. Of the 5 complete calendar years on file, 0 finished higher.

Peer Comparison

C4 Therapeutics, Inc. (CCCC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
C4 Therapeutics, Inc. CCCC $462.57M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. C4 Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Visit website →